BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11890935)

  • 21. Mutation spectrum of MSH3-deficient HHUA/chr.2 cells reflects in vivo activity of the MSH3 gene product in mismatch repair.
    Tauchi H; Komatsu K; Ishizaki K; Yatagai F; Kato T
    Mutat Res; 2000 Feb; 447(2):155-64. PubMed ID: 10751599
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased mutation frequency and altered spectrum in one of four thymic lymphomas derived from tumor prone p53/Big Blue double transgenic mice.
    Buettner VL; Hill KA; Nishino H; Schaid DJ; Frisk CS; Sommer SS
    Oncogene; 1996 Dec; 13(11):2407-13. PubMed ID: 8957082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Elevated mutant frequencies and predominance of G:C to A:T transition mutations in Msh6(-/-) small intestinal epithelium.
    Mark SC; Sandercock LE; Luchman HA; Baross A; Edelmann W; Jirik FR
    Oncogene; 2002 Oct; 21(46):7126-30. PubMed ID: 12370835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner.
    Sansom OJ; Toft NJ; Winton DJ; Clarke AR
    Oncogene; 2001 Jun; 20(27):3580-4. PubMed ID: 11429706
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.
    Casey G; Lindor NM; Papadopoulos N; Thibodeau SN; Moskow J; Steelman S; Buzin CH; Sommer SS; Collins CE; Butz M; Aronson M; Gallinger S; Barker MA; Young JP; Jass JR; Hopper JL; Diep A; Bapat B; Salem M; Seminara D; Haile R;
    JAMA; 2005 Feb; 293(7):799-809. PubMed ID: 15713769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer.
    Chen Y; Wang J; Fraig MM; Henderson K; Bissada NK; Watson DK; Schweinfest CW
    Int J Oncol; 2003 May; 22(5):1033-43. PubMed ID: 12684669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Female embryonic lethality in mice nullizygous for both Msh2 and p53.
    Cranston A; Bocker T; Reitmair A; Palazzo J; Wilson T; Mak T; Fishel R
    Nat Genet; 1997 Sep; 17(1):114-8. PubMed ID: 9288110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
    Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
    Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of Red Meat and Resistant Starch in Promutagenic Adduct Formation, MGMT Repair, Thymic Lymphoma and Intestinal Tumourigenesis in Msh2 -Deficient Mice.
    Winter JM; Hu Y; Young GP; Kohonen-Corish MR; Le Leu RK
    J Nutrigenet Nutrigenomics; 2014; 7(4-6):299-313. PubMed ID: 26022687
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunohistochemistry for MSH2 and MHL1: a method for identifying mismatch repair deficient colorectal cancer.
    Stone JG; Robertson D; Houlston RS
    J Clin Pathol; 2001 Jun; 54(6):484-7. PubMed ID: 11376026
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Two mismatch repair gene mutations found in a colon cancer patient--which one is pathogenic?
    Kariola R; Otway R; Lönnqvist KE; Raevaara TE; Macrae F; Vos YJ; Kohonen-Corish M; Hofstra RM; Nyström-Lahti M
    Hum Genet; 2003 Feb; 112(2):105-9. PubMed ID: 12522549
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differing patterns of genetic instability in mice deficient in the mismatch repair genes Pms2, Mlh1, Msh2, Msh3 and Msh6.
    Hegan DC; Narayanan L; Jirik FR; Edelmann W; Liskay RM; Glazer PM
    Carcinogenesis; 2006 Dec; 27(12):2402-8. PubMed ID: 16728433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toward new strategies to select young endometrial cancer patients for mismatch repair gene mutation analysis.
    Berends MJ; Wu Y; Sijmons RH; van der Sluis T; Ek WB; Ligtenberg MJ; Arts NJ; ten Hoor KA; Kleibeuker JH; de Vries EG; Mourits MJ; Hollema H; Buys CH; Hofstra RM; van der Zee AG
    J Clin Oncol; 2003 Dec; 21(23):4364-70. PubMed ID: 14645426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Altered expression and new mutations in DNA mismatch repair genes MLH1 and MSH2 in melanoma brain metastases.
    Korabiowska M; König F; Verheggen R; Schlott T; Cordon-Cardo C; Romeike B; Brinck U
    Anticancer Res; 2004; 24(2B):981-6. PubMed ID: 15161053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective radiosensitization of drug-resistant MutS homologue-2 (MSH2) mismatch repair-deficient cells by halogenated thymidine (dThd) analogues: Msh2 mediates dThd analogue DNA levels and the differential cytotoxicity and cell cycle effects of the dThd analogues and 6-thioguanine.
    Berry SE; Davis TW; Schupp JE; Hwang HS; de Wind N; Kinsella TJ
    Cancer Res; 2000 Oct; 60(20):5773-80. PubMed ID: 11059773
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
    Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
    Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Deficiency in Msh2 affects the efficiency and local sequence specificity of immunoglobulin class-switch recombination: parallels with somatic hypermutation.
    Ehrenstein MR; Neuberger MS
    EMBO J; 1999 Jun; 18(12):3484-90. PubMed ID: 10369687
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse mismatch repair gene Msh2 is not essential for transcription-coupled repair of UV-induced cyclobutane pyrimidine dimers.
    Sonneveld E; Vrieling H; Mullenders LH; van Hoffen A
    Oncogene; 2001 Jan; 20(4):538-41. PubMed ID: 11313985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunohistochemistry and microsatellite instability testing for selecting MLH1, MSH2 and MSH6 mutation carriers in hereditary non-polyposis colorectal cancer.
    Caldés T; Godino J; Sanchez A; Corbacho C; De la Hoya M; Lopez Asenjo J; Saez C; Sanz J; Benito M; Ramon Y Cajal S; Diaz-Rubio E
    Oncol Rep; 2004 Sep; 12(3):621-9. PubMed ID: 15289847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of Bcl11b genotypes and gamma-radiation on the development of mouse thymic lymphomas.
    Yoshikai Y; Sato T; Morita S; Kohara Y; Takagi R; Mishima Y; Kominami R
    Biochem Biophys Res Commun; 2008 Aug; 373(2):282-5. PubMed ID: 18558082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.